Previous 10 | Next 10 |
home / stock / rmd / rmd articles
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 4.34% on an annualized basis producing an average annual return of 16.13%. ...
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 7.47% on an annualized basis producing an average annual return of 15.05%. ...
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) announced that it has secured a significant victory after the United S...
Justin Leong appointed Chief Product Officer, effective immediately. Katrin Pucknat appointed Chief Marketing Officer, effective immediately. Mik...
Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE: RMD) with a price target of $180. ResMed registered a...
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the s...
Needham upgraded ResMed Inc (NYSE: RMD) from a Hold to Buy rating with a price target of $180. The analysts Mike Matson, J...
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced its participation in two upcoming conferences. Mick F...
Wells Fargo raised the price target for Equity Residential (NYSE: EQR) from $62 to $69. Wells Fargo analyst James Feldman upgraded the stock fro...
News, Short Squeeze, Breakout and More Instantly...
2024-06-29 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. He...
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7%...